Eli Lilly broke ground on a $6.5 billion oral GLP-1 manufacturing facility in Houston, positioning the site as one of ten planned U.S. locations supporting domestic production for obesity and related indications. The facility will primarily focus on producing orforglipron (Foundayo), a once-daily oral GLP-1 receptor agonist approved in the U.S. Lilly framed the investment as part of a broader onshoring strategy aimed at stabilizing supply and reducing risk of shortages. The company also highlighted workforce development partnerships, including training ties with San Jacinto College. For the biotech supply chain, the project is a signal that demand growth for oral incretin therapies is now driving large-scale capacity expansion in API and drug product manufacturing rather than relying exclusively on distributed global supply lines.